Chemotherapy Resistance in Advanced Ovarian Cancer Patients.

Biomarkers in cancer Pub Date : 2019-07-05 eCollection Date: 2019-01-01 DOI:10.1177/1179299X19860815

Ruchika Pokhriyal, Roopa Hariprasad, Lalit Kumar, Gururao Hariprasad

{"title":"Chemotherapy Resistance in Advanced Ovarian Cancer Patients.","authors":"Ruchika Pokhriyal, Roopa Hariprasad, Lalit Kumar, Gururao Hariprasad","doi":"10.1177/1179299X19860815","DOIUrl":null,"url":null,"abstract":"<p><p>Ovarian cancer is the seventh most common gynaecologic malignancy seen in women. Majority of the patients with ovarian cancer are diagnosed at the advanced stage making prognosis poor. The standard management of advanced ovarian cancer includes tumour debulking surgery followed by chemotherapy. Various types of chemotherapeutic regimens have been used to treat advanced ovarian cancer, but the most promising and the currently used standard first-line treatment is carboplatin and paclitaxel. Despite improved clinical response and survival to this combination of chemotherapy, numerous patients either undergo relapse or succumb to the disease as a result of chemotherapy resistance. To understand this phenomenon at a cellular level, various macromolecules such as DNA, messenger RNA and proteins have been developed as biomarkers for chemotherapy response. This review comprehensively summarizes the problem that pertains to chemotherapy resistance in advanced ovarian cancer and provides a good overview of the various biomarkers that have been developed in this field.</p>","PeriodicalId":72377,"journal":{"name":"Biomarkers in cancer","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613062/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1179299X19860815","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Ovarian cancer is the seventh most common gynaecologic malignancy seen in women. Majority of the patients with ovarian cancer are diagnosed at the advanced stage making prognosis poor. The standard management of advanced ovarian cancer includes tumour debulking surgery followed by chemotherapy. Various types of chemotherapeutic regimens have been used to treat advanced ovarian cancer, but the most promising and the currently used standard first-line treatment is carboplatin and paclitaxel. Despite improved clinical response and survival to this combination of chemotherapy, numerous patients either undergo relapse or succumb to the disease as a result of chemotherapy resistance. To understand this phenomenon at a cellular level, various macromolecules such as DNA, messenger RNA and proteins have been developed as biomarkers for chemotherapy response. This review comprehensively summarizes the problem that pertains to chemotherapy resistance in advanced ovarian cancer and provides a good overview of the various biomarkers that have been developed in this field.

查看原文本刊更多论文

晚期卵巢癌患者的化疗耐药

卵巢癌是女性第七大常见妇科恶性肿瘤。大多数卵巢癌患者诊断为晚期，预后较差。晚期卵巢癌的标准治疗包括肿瘤缩小手术和化疗。各种类型的化疗方案已被用于治疗晚期卵巢癌，但最有希望和目前使用的标准一线治疗是卡铂和紫杉醇。尽管这种联合化疗改善了临床反应和生存率，但许多患者由于化疗耐药性而复发或死于疾病。为了在细胞水平上理解这一现象，各种大分子如DNA、信使RNA和蛋白质已被开发作为化疗反应的生物标志物。本文全面总结了晚期卵巢癌化疗耐药的相关问题，并对该领域开发的各种生物标志物进行了概述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in cancer

自引率

0.00%

发文量